Manufacturing Automated
creation
In many cases, pharmaceutical production is a relatively hands-off affair, with specialised machinery carrying out much of the work that was once done by hand. But when it comes to products with live cells inside and the financial risk of them failing, automated production becomes a much more complex issue. That said, there are still companies trying to make automated cell and gene therapy production a reality; Michele Brailsford speaks to
Dr Qasim Rafiq, associate professor of Cell and Gene Therapy Bioprocess Engineering at University College London, to discover some of the innovations that could help accelerate the manufacture of what many believe to be the next frontier in pharmaceutical medicine.
magine a world where there is no need for cancer patients to have invasive therapies like surgery, chemotherapy or radiotherapy; where patients with rare diseases that can occur due to genetic abnormalities, such as leukaemia and multiple myeloma, can be treated and even cured using personalised cell and gene therapy (CGT) treatments. Often referred to as revolutionary in medicine, CGT can alter the genetic instruction of a patient’s cells by replacing faulty or missing genes with healthy ones, or changing the way they are regulated so they can operate normally. Leading the way is CAR-T cell therapy, which has cured advanced forms of leukaemia
I 40 World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Rawpixel.com/
Shutterstock.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
